Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis

Primary Osteoporosis Clinical Trial

Official title:
Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis - Comparative Study With Sodium Risedronate Hydrate(RIS) With Vertebral Fracture as an Index -

Status Completed

Clinical Trial Summary

To evaluate the efficacy and safety of R484iv by intravenous intermittent administration to patients with primary osteoporosis in comparison with sodium risedronate hydrate (RIS) by oral administration every day. To evaluate also the dose response of R484iv.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00447915
Study type	Interventional
Source	Chugai Pharmaceutical
Contact
Status	Completed
Phase	Phase 3
Start date	March 2007
Completion date	December 2011

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT02142348` - Longitudinal Study of Primary Osteoporosis in Shanghai Postmenopausal Women	N/A
Not yet recruiting	`NCT05370898` - The Study of Chinese Medicine for the Treatment of Primary Osteoporosis	N/A
Recruiting	`NCT05606510` - The Effects of Mindful Exercise on Back Pain in Older Patients With Primary Osteoporosis	N/A